ABM Therapeutics Completes $20 Million Round for Neural Cancer Drugs

ABM Therapeutics of Shanghai completed a $20 million Series A+ round. Founded in 2015, ABM develops small molecule drugs that cross the blood-brain barrier. The company has one candidate, ABM-1310, in clinical trials for glioblastoma along with several preclinical projects that are designed to cross the blood-brain barrier and treat brain metastasis from melanoma, lung and breast cancer. The A+ round was led by Huachuang Capital. More details.... Share this with colleagues: // // <br /